RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer Twenty-four patients received vismodegib; five were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results